Evvy, an Amboy Street Portfolio Company, Raises a $14M SeriesA

Amboy Street Ventures announces its latest investment in Evvy, a company committed to restoring equity in healthcare by leveraging overlooked female biomarkers, starting with the vaginal microbiome.

In 2021, Evvy launched the at-home vaginal microbiome test leveraging metagenomic sequencing to elucidate what’s up down there. Insights from their test led to the expansion of Evvy’s innovative vaginal health platform, combining state-of-the-art testing, precision care, and proactive tracking to give women and people with vaginas the healthcare they deserve. Through this platform, Evvy is building the datasets necessary to revolutionize reproductive and female-focused healthcare.

Founded by Priyanka Jain, Laine Bruzek, and Pita Navarro, the Evvy team reflects talent from across disciplines with decades of experience at organizations like UCSF, Stanford and Harvard including a group of leading OB/GYNs, and vaginal microbiome researchers.

Since launch, Evvy has generated the world’s most comprehensive dataset on the vaginal microbiome, completed an IRB-approved clinical study to validate the efficacy of Evvy’s care platform and created and celebrated two Equal Research Days (like Equal Pay Day but for the gender health gap), mobilizing hundreds of doctors, celebrities, patients, and investors.

Amboy Street is excited to support Evvy alongside notable co-investors Left Lane Capital, General Catalyst and Labcorp Venture Fund. With the funding, Evvy will continue to build out their R&D platform and precision vaginal healthcare offering — which now includes STI testing & treatment.

Carli Sapir of Amboy Street Ventures is excited for what the future holds for Evvy: “Understanding the vaginal microbiome is imperative to understanding overall wellbeing of women. As the number one reason that women go to the doctor is for vaginal discomfort, Evvy is clearly meeting a huge unmet need. I am thrilled to support Evvy as the founders take massive strides to close the gender health gap.”

Evvy is one of ASV’s growing portfolio of brands pioneering women’s health and sexual health solutions alongside Hey Jane, leading telehealth abortion provider, Contraline, the maker of male birth control and Dame Products, a leading female-focused sexual wellness brand. See the full portfolio here. To learn more about Evvy visit www.evvy.com and follow Evvy on Instagram (@evvy) and TikTok (@evvybio).

We are thrilled to be supporting Evvy as they grow and look forward to making more investments in women’s health and sexual health. Stay tuned!

Continue Reading

Amboy Street Invests in Alloy’s $16M Series A

Amboy Street Ventures is excited to announce its latest investment in Alloy Women’s Health, a digital health company committed to providing women the care they need through menopause and beyond.

Top 10 Deals of 2024: BillionToOne Becomes a Unicorn

In this blog, we unpack prenatal genetic screening company, BillionToOne's $130 million Series D raise to showcase the increasing number of women’s health companies reaching unicorn status. We are seeing women’s health companies close considerable growth rounds while early-stage funding remains robust.

Top 10 Deals of 2024: Urinary Incontinence MedTech $3.7B Acquisition

This week we explore a major acquisition in a segment of women’s health that is often stigmatized yet universally experienced by women at some point in their lifetime: urinary incontinence.

Amboy Street Invests in Alloy’s $16M Series A

Amboy Street Ventures is excited to announce its latest investment in Alloy Women’s Health, a digital health company committed to providing women the care they need through menopause and beyond.

Top 10 Deals of 2024: BillionToOne Becomes a Unicorn

In this blog, we unpack prenatal genetic screening company, BillionToOne's $130 million Series D raise to showcase the increasing number of women’s health companies reaching unicorn status. We are seeing women’s health companies close considerable growth rounds while early-stage funding remains robust.

Fast track our industry.
Get in touch today.